Telix Pharmaceuticals (ASX:TLX) has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Australian Therapeutic Goods Administration (TGA) to commence a Phase III clinical trial of the company’s PSMA targeted prostate cancer therapy candidate TLX591 in patients with advanced metastatic castrate-resistant prostate cancer (mCRPC).
The Phase III ProstACT trial is an international, multi-centre, randomised controlled trial (RCT) in patients with PSMA-expressing mCRPC, experiencing disease progression following prior treatment with a novel androgen axis drug (NAAD).
The ProstACT trial will enrol approximately 390 patients and incorporates patient selection using Ga-PSMA imaging with TLX591-CDx (Illuccix). The trial will compare standard of care therapy alone versus standard of care therapy plus TLX591, with a primary endpoint of radiographic progression-free survival (rPFS). Trial secondary endpoints will include overall survival and quality-of-life assessment.
CEO, Dr Christian Behrenbruch, said Telix has commenced the initiation of Australian ProstACT trial sites and will add global sites progressively during the second half of 2021, subject to the requisite approvals.
The commencement of the ProstACT Phase III study for TLX591 marks a major corporate milestone for Telix that brings the company a step closer to delivering on a major unmet medical need for treatment options in this patient population,” Dr Christian Behrenbruch said.
ProstACT builds on a significant body of clinical data for TLX591, which to date has been studied in over 200 patients with advanced prostate cancer, across five previous studies. TLX591 has demonstrated promising and competitive clinical potential that we believe warrants further confirmation in this second-line disease setting. It is also noteworthy that Telix’s differentiated approach to integrating molecular imaging with PET alongside therapy, enables a comparatively streamlined study that we believe will support efficient patient enrolment and study execution.”
Prostate cancer is the second most common cancer in men after skin cancer and worldwide 1.4 million men were diagnosed with prostate cancer in 2020. Despite advances in treatment, prostate cancer still accounts for a large number of deaths and in 2020 more than 375,000 men died from their disease. Rates of diagnosis are increasing, and the highest incidences of prostate cancer are found in the United States, Europe, Australia and New Zealand.
